Updated: Bayer cuts PhII orphan drug as it ups R&D spending, questions swirl around new CEO’s next moves

Amber Tong

Reynald Castañeda

Deputy Editor

Bayer has shuttered a Phase II program that the EMA had designated an orphan drug “for scientific reasons,” the German conglomerate disclosed in its half …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Bayer cuts PhII orphan drug as it ups R&D spending, questions swirl around new CEO’s next moves

Amber Tong

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Up­dat­ed: Bay­er cuts PhII or­phan drug as it ups R&D spend­ing, ques­tions swirl around new CEO’s next moves

Deputy Editor

Sign up to read this article for free.

Updated: Bayer cuts PhII orphan drug as it ups R&D spending, questions swirl around new CEO’s next moves